Twenty four genetic variants linked to heightened womb cancer risk

February 17, 2020

Twenty four common variations in genes coding for cell growth and death, the processing of oestrogen, and gene control factors may be linked to a heightened risk of developing womb (endometrial) cancer, indicates the most comprehensive review of the published evidence so far in the Journal of Medical Genetics.

Women with all or most of these variants may run two to three times the risk of developing the disease, which is the most common gynaecological cancer in the developed world, say the researchers.

In the US women have an estimated 1 in 35 lifetime risk of being diagnosed with womb cancer, and the death toll from the disease has risen by 2% every year since 2008.

Inherited susceptibility accounts for only a small proportion of cases (3-5%), with most cases thought to be spontaneous or related to lifestyle factors.

There are two types of womb cancer: type I, which is usually diagnosed at an early stage, and is treatable; and type II, which is aggressive, often diagnosed late, and has a poor outlook.

Trying to pinpoint genetic factors that may increase the risk is therefore important. And previous research has implicated differences in just one DNA building block (nucleotide), known as single nucleotide polymorphisms, or SNPs for short.

SNPs are common, with around 4 to 5 million in an individual's complete genetic code (genome). These variations may be unique to that person or occur in many people.

Most SNPs don't affect health or development. But when they arise in a gene or in a regulatory region near one, they may affect that gene's function and boost the risk of disease.

Previous research has implicated SNPs in womb cancer risk, but the quality of these studies varies considerably and they were mostly carried out before the advent of whole genome association studies.

The researchers therefore systematically reviewed relevant research, published between 2007 and 2018, to see if there was any association between SNPs and endometrial cancer risk and came up with 149 studies out of an initial 453.

They found that 24 common SNPs in or around six genes, coding for cell growth and death, the processing of oestrogen, and gene control factors (transcription control), were strongly associated with the development of womb cancer.

Nineteen of these genetic variants were statistically significant, while five were suggestive of disease risk. But no convincing evidence was found for the most widely studied (to date) genetic variant in womb cancer.

Women with most or all of these 24 genetic variants would be expected to be twice or three times as likely to develop womb cancer as those without, calculate the researchers.

There are likely to be more SNPs involved in womb cancer development, they add: hundreds have been implicated in breast cancer, for example.

But these 24 could be used to come up with a personalised risk score for women most at risk of womb cancer, to boost early detection and/or preventive treatment efforts, they suggest.
-end-
Peer reviewed? Yes
Evidence type: Systematic review
Subjects: People

BMJ

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.